New deals this week span across ophthalmology to Alzheimer’s, with three new acquisitions and one research collaboration.
FDA has approved Gazyva (obinutuzumab) for the treatment of adult patients with primary membranous nephropathy (pMN) at risk ...
FDA approves three new therapies, a wave of dealmaking led by Johnson & Johnson, Eli Lilly, AmyriAD Therapeutics, and Sanofi, ...
Sustainable competitive advantage requires combining proprietary evidence, AI, and human expertise—not substituting one for ...
Moderna used its 2026 Analyst Day to outline an oncology-driven growth strategy anchored by intismeran and other cancer antigen therapies.
Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from ...
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter ...
The agreement provides access for prescribed patients to Lilly's obesity medicines self-pay pricing starting at $149 per ...
FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention. FDA has granted ...
As Medicare negotiation, PBM reform, and cash-pay channels converge, winning on auditable net value matters more than cutting ...
Moderna lays out an oncology-driven growth plan at its 2026 Analyst Day, Pfizer and Blackstone sign a co-funding deal worth ...